Anixa Biosciences Inc (NASDAQ:ANIX – Get Free Report) CEO Amit Kumar bought 5,000 shares of the firm’s stock in a transaction that occurred on Friday, October 30th. The shares were acquired at an average cost of $3.17 per share, for a total transaction of $15,850.00. Following the completion of the acquisition, the chief executive officer directly owned 685,000 shares in the company, valued at $2,171,450. The trade was a 0.74% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Amit Kumar also recently made the following trade(s):
- On Thursday, October 22nd, Amit Kumar acquired 8,000 shares of Anixa Biosciences stock. The stock was acquired at an average cost of $2.72 per share, with a total value of $21,760.00.
- On Thursday, September 24th, Amit Kumar purchased 7,000 shares of Anixa Biosciences stock. The stock was acquired at an average price of $2.78 per share, for a total transaction of $19,460.00.
- On Thursday, September 10th, Amit Kumar purchased 3,000 shares of Anixa Biosciences stock. The shares were purchased at an average cost of $2.75 per share, for a total transaction of $8,250.00.
- On Thursday, September 10th, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The shares were bought at an average price of $2.76 per share, with a total value of $13,800.00.
Anixa Biosciences Stock Performance
Shares of NASDAQ:ANIX traded down $0.07 during midday trading on Monday, reaching $3.05. The company’s stock had a trading volume of 51,734 shares, compared to its average volume of 208,651. The firm has a market capitalization of $106.02 million, a price-to-earnings ratio of -9.53 and a beta of 0.47. The firm has a 50 day moving average price of $2.97 and a two-hundred day moving average price of $2.97. Anixa Biosciences Inc has a fifty-two week low of $2.32 and a fifty-two week high of $5.46.
Anixa Biosciences (NASDAQ:ANIX – Get Free Report) last posted its earnings results on Wednesday, September 9th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). As a group, research analysts anticipate that Anixa Biosciences Inc will post -0.31 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of ANIX. BlackRock Inc. purchased a new position in shares of Anixa Biosciences during the 2nd quarter valued at about $559,000. GSA Capital Partners LLP purchased a new position in shares of Anixa Biosciences in the second quarter valued at about $329,000. CoreCap Advisors LLC boosted its stake in shares of Anixa Biosciences by 19.2% in the third quarter. CoreCap Advisors LLC now owns 62,020 shares of the company’s stock worth $182,000 after acquiring an additional 10,000 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Anixa Biosciences by 13.6% in the first quarter. Renaissance Technologies LLC now owns 61,173 shares of the company’s stock worth $158,000 after acquiring an additional 7,300 shares during the period. Finally, Kestra Advisory Services LLC lifted its holdings in Anixa Biosciences by 96.2% in the 1st quarter. Kestra Advisory Services LLC now owns 51,000 shares of the company’s stock worth $132,000 after purchasing an additional 25,000 shares in the last quarter. Institutional investors own 29.13% of the company’s stock.
Analyst Ratings Changes
A number of research firms have recently weighed in on ANIX. Weiss Ratings raised Anixa Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 17th. Wall Street Zen cut Anixa Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday. HC Wainwright reduced their price target on Anixa Biosciences from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, September 22nd. Citigroup reissued a “buy” rating on shares of Anixa Biosciences in a research report on Tuesday, October 6th. Finally, Zacks Research cut shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $8.00.
Read Our Latest Stock Analysis on Anixa Biosciences
About Anixa Biosciences
Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. The company’s programs are designed to use the immune system to identify and attack disease-associated targets.
Anixa’s oncology pipeline has included a chimeric antigen receptor T-cell (CAR-T) therapy targeting the follicle-stimulating hormone receptor, which is being investigated as a potential treatment for ovarian cancer and other cancers.
Read More
- Five stocks we like better than Anixa Biosciences
- Strategy Pauses Bitcoin Buys to Focus on Preferred Stock Buybacks
- Uranium Prices Are Near Historic Highs—So Why Hasn’t Cameco Followed?
- Royal Caribbean Buys the Beach as Norwegian Fixes the Ship
- SK hynix Says Memory Demand Beats Supply Through 2030—What It Means for Micron and SanDisk
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
